Abstract
Targeting tumor angiogenesis to treat cancer has been the focus of intense research in recent decades. The resulting increase in our knowledge of cancer biology has lead to the development of several new classes of investigational agents that inhibit the angiogenic process. While many clinical trials on antiangiogenic compounds have had disappointing results, the recent approval of the first effective drug targeting tumor vessels has revived interest in further drug development for angiogenesis inhibitors. Of the plethora of new patents for antiangiogenic compounds, only a few describe compounds that will become effective and non-toxic therapies for patients with cancer. This review examines representative patents related to cancer angiogenesis in the context of our current knowledge of the biological processes leading to tumor vascularization and explores the future of multi-targeted therapy and nanoformulation technology in the field of angiogenic therapy.
Keywords: Tumor angiogenesis, vascular endothelial growth factor, indolinones
Recent Patents on Anti-Cancer Drug Discovery
Title: Review of Selected Patents for Cancer Therapy Targeting Tumor Angiogenesis
Volume: 1 Issue: 2
Author(s): Mark N. Kirstein, Megan M. Moore and Arkadiusz Z. Dudek
Affiliation:
Keywords: Tumor angiogenesis, vascular endothelial growth factor, indolinones
Abstract: Targeting tumor angiogenesis to treat cancer has been the focus of intense research in recent decades. The resulting increase in our knowledge of cancer biology has lead to the development of several new classes of investigational agents that inhibit the angiogenic process. While many clinical trials on antiangiogenic compounds have had disappointing results, the recent approval of the first effective drug targeting tumor vessels has revived interest in further drug development for angiogenesis inhibitors. Of the plethora of new patents for antiangiogenic compounds, only a few describe compounds that will become effective and non-toxic therapies for patients with cancer. This review examines representative patents related to cancer angiogenesis in the context of our current knowledge of the biological processes leading to tumor vascularization and explores the future of multi-targeted therapy and nanoformulation technology in the field of angiogenic therapy.
Export Options
About this article
Cite this article as:
Kirstein N. Mark, Moore M. Megan and Dudek Z. Arkadiusz, Review of Selected Patents for Cancer Therapy Targeting Tumor Angiogenesis, Recent Patents on Anti-Cancer Drug Discovery 2006; 1 (2) . https://dx.doi.org/10.2174/157489206777442269
DOI https://dx.doi.org/10.2174/157489206777442269 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nitric Oxide: Cancer Target or Anticancer Agent?
Current Cancer Drug Targets Cyclooxygenase-2: Potential Role in Regulation of Drug Efflux and Multidrug Resistance Phenotype
Current Pharmaceutical Design Heterocyclic Drug-polymer Conjugates for Cancer Targeted Drug Delivery
Anti-Cancer Agents in Medicinal Chemistry Progress on Multi-Modality Molecular Imaging
Current Medical Imaging Mitochondrial Dysfunction in Gliomas: Pharmacotherapeutic Potential of Natural Compounds
Current Neuropharmacology Stem Cells in Brain Tumorigenesis and their Impact on Therapy
Current Stem Cell Research & Therapy Astrocytes: Implications for Neuroinflammatory Pathogenesis of Alzheimers Disease
Current Alzheimer Research Prospects of Non-Coding Elements in Genomic DNA Based Gene Therapy
Current Gene Therapy Endomorphin Derivatives with Improved Pharmacological Properties
Current Medicinal Chemistry Iron Oxide Nanoparticle Platform for Biomedical Applications
Current Medicinal Chemistry Cell Cycle as a Target of Antineoplastic Drugs
Current Pharmaceutical Design P-Glycoprotein and Breast Cancer Resistance Protein Affect Disposition of Tandutinib, A Tyrosine Kinase Inhibitor
Drug Metabolism Letters Post-Translational Modifications of PTEN and their Potential Therapeutic Implications
Current Cancer Drug Targets Doxycycline as Potential Anti-cancer Agent
Anti-Cancer Agents in Medicinal Chemistry Voltage-Gated Ion Channels, New Targets in Anti-Cancer Research
Recent Patents on Anti-Cancer Drug Discovery Editorial [Hot Topic: Angiogenesis Agents (Executive Editor: Cezary Marcinkiewicz)]
Current Pharmaceutical Design An Update on Circumventing Multidrug Resistance in Cancer by Targeting P-Glycoprotein
Current Cancer Drug Targets Combining Angiogenesis Inhibitors with Radiation: Advances and Challenges in Cancer Treatment
Current Pharmaceutical Design NEDD4: A Promising Target for Cancer Therapy
Current Cancer Drug Targets Fluoride Interactions: From Molecules to Disease
Current Signal Transduction Therapy